Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
FDA
Sort By
Newest First
1 / 25
FDA
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration
HuidaGene Therapeutics
PR-10-24-NI-81
Nov 07, 2024
Clinical Treatment
Eisai Completes Submission to US FDA for LEQEMBI Application for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Eisai
PR-10-24-NI-70
Nov 01, 2024
QbD
Designing Quality into Biomanufacturing
Miguel Carrion; Michelle Kneeland
Tanvex CDMO
PAO-10-24-CL-09
Oct 29, 2024
Clinical Trials
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax
PR-10-24-NI-48
Oct 17, 2024
FDA
U.S. Food and Drug Administration
U.S. Food & Drug Administration
PR-10-24-NI-44
Oct 14, 2024
FDA
FDA Approves IMULDOSA, Accord BioPharma's Biosimilar to STELARA, for the Treatment of Chronic Inflammatory Conditions
Accord Biopharma
PR-10-24-NI-43
Oct 14, 2024
FDA
SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia
Systimmune, Inc.
PR-10-24-NI-42
Oct 14, 2024
Clinical Trials
StemCyte's HPC Cord Blood Receives RMAT Designation for Long COVID-19 Treatment
StemCyte
PR-09-24-NI-28
Oct 07, 2024
FDA
Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment
Thryv Therapeutics Inc
PR-09-24-NI-27
Oct 03, 2024
FDA
PTC Therapeutics Announces FDA Acceptance for Filing of NDA for the Treatment of Pediatric and Adult Phenylketonuria Patients
PTC Therapeutics, Inc.
PR-09-24-NI-26
Oct 03, 2024
Clinical Trails
TALVEY and TECVAYLI suggests high response rates in triple-class refractory patients with relapsed or refractory multiple myeloma
Johnson & Johnson
PR-09-24-NI-20
Sep 27, 2024
CDMO
FDA Approves First Treatment for Niemann-Pick Disease, Type C
U.S. Food & Drug Administration
PR-09-24-NI-12
Sep 23, 2024
CDMO
UCB Announces FDA Approvals for BIMZELX for Psoriatic Arthritis, Axial Spondyloarthritis, and Ankylosing Spondylitis
UCB
PR-09-24-NI-13
Sep 23, 2024
Cell and Gene Therapy Regulatory
Navigating Regulatory Complexity for Cell and Gene Therapies
Natasha Rivas
PAO-04-24-CL-03
Apr 12, 2024
mRNA–LNP Manufacturing
The Innovators Bringing Continuous Manufacturing to Lipid Nanoparticles
Antonio Costa, Ph.D.; William Pasek
DIANT Pharma
PAO-03-24-CL-08
Mar 18, 2024
Nitrosamine Impurities
Addressing the Evolving Nitrosamine Contamination Issue
Olon
PAO-09-23-CL-07
Sep 15, 2023
Continuous Processing
US Food and Drug Administration (FDA) Purchase the LiFT System from DIANT® Pharma INC.
DIANT Pharma
PR-M07-23-03
Jul 31, 2023
Cultivated Meat
Leveraging Biopharma Sensor Technologies for Cultivated Meat Processes
Giovanni Campolongo
Hamilton
PAO-05-23-CL-02
May 17, 2023
Cosmeceuticals
Cosmeceuticals Are Here. When Will Regulations Catch Up?
Ameena Pathan
That's Nice LLC
PAO-08-022-CL-09
Aug 31, 2022
Column: Regulatory Spotlight
The Price of Pain: Acknowledging a Crisis and Encouraging an Alternative
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-022--NI-05
Jun 24, 2022
1 / 25
